Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

S.J & G. Fazul Ellahie (pvt) limited.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000083 193 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx193product presentations
G68generic molecules
DF7dosage-form groups
TA12therapeutic areas
PKR193current price records
REG160registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage99%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixS.J & G. Fazul Ellahie (pvt) limited.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/s-j-g-fazul-ellahie-pvt-limitedGenerated 10 Aug 2026Anti-infectives113 · 59%Gastrointestinal & hepatology21 · 11%CNS & mental health16 · 8%Vitamins, minerals & nutrition15 · 8%Cardiovascular7 · 4%Pain & musculoskeletal7 · 4%Respiratory & allergy5 · 3%Other therapeutic areas9 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioS.J & G. Fazul Ellahie (pvt) limited.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/s-j-g-fazul-ellahie-pvt-limitedGenerated 10 Aug 2026193presentationsTablet70 · 36%Injection64 · 33%Capsule20 · 10%Suspension17 · 9%Infusion10 · 5%Syrup9 · 5%Other forms3 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionS.J & G. Fazul Ellahie (pvt) limited.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/s-j-g-fazul-ellahie-pvt-limitedGenerated 10 Aug 2026178comparable productsBelow market median41 · 23%Near market median90 · 51%Above market median47 · 26%Company median price position+1.4%Lowest-price equivalents15Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsS.J & G. Fazul Ellahie (pvt) limited.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/s-j-g-fazul-ellahie-pvt-limitedGenerated 10 Aug 2026Neutro Pharma (Pvt.) Ltd.,41 shared60% overlapMediate Pharmaceutical Pvt Ltd38 shared56% overlapNabiqasim Industries (Pvt) Ltd.,37 shared54% overlapBosch Pharmaceuticals (Pvt) Ltd.37 shared54% overlapBio-Labs(Pvt) Ltd37 shared54% overlapMacter International Limited35 shared51% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives113 products · 59%
Gastrointestinal & hepatology21 products · 11%
CNS & mental health16 products · 8%
Vitamins, minerals & nutrition15 products · 8%
Cardiovascular7 products · 4%
Pain & musculoskeletal7 products · 4%
Respiratory & allergy5 products · 3%
Fluids & supportive care3 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins20 products · 10%
Vitamins / minerals / hematinics15 products · 8%
Fluoroquinolone antibacterials15 products · 8%
Antivirals12 products · 6%
Antiemetics11 products · 6%
Antimalarials11 products · 6%
Oxazolidinone antibacterials11 products · 6%
Macrolide antibacterials11 products · 6%
Formulation footprint

Dosage forms

Tablet70 products
Injection64 products
Capsule20 products
Suspension17 products
Infusion10 products
Syrup9 products
Solution3 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 VifyOmeprazole 10presentations 10 mg, 20 mg, 40 mg · Capsule, Injection #2 NezkilLinezolid 8presentations 100 mg/5 mL, 400 mg, 600 mg · Suspension, Tablet, Infusion #3 CefastCeftriaxone 7presentations 1 g, 2 g, 250 mg, 500 mg · Injection #4 CinofloxCiprofloxacin 7presentations 100 mg/50 mL, 125 mg/5 mL, 200 mg/100 mL, 250 mg · Infusion, Suspension, Injection #5 ZeclarClarithromycin 6presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Tablet, Injection #6 FenuronIbuprofen 5presentations 200 mg, 400 mg, 400 mg/4 mL, 800 mg/8 mL · Tablet, Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median4123% of comparable products
Near market median90within ±5% of median
Above market median4726% of comparable products
Lowest-price equivalents15ties included
Company median price position +1.4% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Rexamol 500 mgParacetamol · Tablet · 1000's PKR 0.49/tablet-86.3% vs market median Seretron 8 mg/4 mLOndansetron · Injection · 4mlx1's PKR 129.25/mL-48.5% vs market median Maparix 500 mgVancomycin · Injection · 25's PKR 670.34/vial/unit-45.6% vs market median Water for Injection 5 mLWater for Injection · Injection · 100 x 5ml PKR 1.10/mL-44.8% vs market median Maparix 500 mgVancomycin · Injection · Vial PKR 698.27/vial/unit-43.3% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 41shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 38shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 37shared generics Bosch Pharmaceuticals (Pvt) Ltd.250 products · 73 generics 37shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 37shared generics Macter International Limited248 products · 91 generics 35shared generics
Regulatory & price activity

Observed database signals

Registration numbers160
Price-history records221
Products with price history27
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

193 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Maparix Vancomycin 500 mg Injection Vial 050695 PKR 698.27 PKR 698.27/vial/unit 43% below median
Maparix 1gm Vancomycin 1 g Injection 25's 083291 PKR 29,087.60 PKR 1,163.50/vial/unit 40% below median
Maparix 1gm Vancomycin 1 g Injection Vial 083291 PKR 1,211.98 PKR 1,211.98/vial/unit 38% below median
Merocon Meropenem 500 mg Injection 25's 048625 PKR 47,882.04 PKR 1,915.28/vial/unit 8% below median
Merocon Meropenem 500 mg Injection 1's 048625 PKR 1,995.09 PKR 1,995.09/vial/unit Near median
Merocon Meropenem 1 g Injection 25's 048626 PKR 89,010.08 PKR 3,560.40/vial/unit 10% below median
Merocon Meropenem 1 g Injection 1's 048626 PKR 3,708.76 PKR 3,708.76/vial/unit 6% below median
Midazole Midazole Metronidazole 500 mg Injection 100ml 023039 PKR 153.50 PKR 1.54/mL 19% below median
Morphine Morphine 15 mg Injection 100 x 1 ml 027913 PKR 727.57 PKR 7.28/mL 61% below median
Moxibact Moxibact Moxifloxacin 400 mg Tablet 5's 037420 PKR 947.67 PKR 189.53/tablet Near median
New-Zone Ceftriaxone 250 mg IV injection 1's 083165 PKR 155.85 PKR 155.85/vial/unit 17% below median
Nezkil Linezolid 100 mg/5 mL Dry suspension 60 ml 067037 PKR 698.27 PKR 11.64/mL 10% above median
Nezkil Linezolid 400 mg Tablet 12's 034783 PKR 2,852.96 PKR 237.75/tablet Near median
Nezkil Linezolid 400 mg IV infusion 200 ml 048803 PKR 868.58 PKR 4.34/mL 10% above median
Nezkil Linezolid 600 mg Tablet 12's 035263 PKR 4,269.47 PKR 355.79/tablet 10% below median
Nezkil Linezolid 600 mg IV infusion 300 ml 048804 PKR 1,197.06 PKR 3.99/mL Near median
Nezkil Linezolid 100 mg/5 mL Dry suspension 120 ml 067037 PKR 1,326.73 PKR 11.06/mL Near median
Nezkil Linezolid 400 mg Tablet 14's 034783 PKR 3,327.79 PKR 237.70/tablet Near median
Nezkil Linezolid 600 mg Tablet 14's 035263 PKR 4,978.47 PKR 355.61/tablet 10% below median
Nezkil Nezkil Linezolid 400 mg Tablet 10's 034783 PKR 2,376.99 PKR 237.70/tablet Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.